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Ghrelin O-acyltransferase (GOAT), a member of MBOATs family, is essential for octanoylation of ghrelin, which is required 
for active ghrelin to bind with and activate its receptor. GOAT is expressed mainly in the stomach, pancreas and hypothalamus. 
Levels of GOAT are altered by energy status. GOAT contains 11 transmembrane helices and one reentrant loop. Its invariant 
residue His-338 and conserved Asn-307 are located in the endoplasmic reticulum lumen and cytosol respectively. GOAT con-
tributes to the regulation of food intake and energy expenditure, as well as glucose and lipids homeostasis. Deletion of GOAT 
blocks the acylation of ghrelin leading to subsequent impairment in energy homeostasis and survival when mice are challenged 
with high energy diet or severe caloric restriction. GO-CoA-Tat, a peptide GOAT inhibitor, attenuates acyl-ghrelin production 
and prevents weight gain induced by a medium-chain triglycerides-rich high fat diet. Further, GO-CoA-Tat increases glu-
cose-induced insulin secretion. Overall, inhibition of GOAT is a novel strategy for treatment of obesity and related metabolic 
disorders. 
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Ghrelin is the only circulating hormone that exhibits potent 
stimulation of food intake. This property of ghrelin has 
made it the focus of studies which explore the molecular 
mechanisms of energy metabolism with the hope of devel-
oping novel therapeutic strategy for obesity and related 
metabolic diseases. The active form of ghrelin contains a 
unique octanoylation site. Search for the octanoylation cat-
alytic enzyme led to the discovery of ghrelin O-acyltrans- 
ferase (GOAT). GOAT is the unique enzyme responsible 
for ghrelin acylation, enabling active ghrelin to bind with its 
receptor, growth hormone secretagogue receptor 1a (GHS- 
R1a). Acyl-ghrelin promotes a positive energy balance by 
increasing food intake and reducing energy expenditure, 
therefore leading to an increase in body weight and adipos-
ity. Further, acyl-ghrelin affects glucose metabolism.  
Ghrelin and its receptor have been targets for therapeutic 
agents against obesity, and more than 20 drugs have target-
ed the ghrelin/GHSR1a system. While ghrelin antagonists 
initially held promise, long term efficacy has been disap-
pointing. Alternative approaches targeting GOAT are ap-
pealing. Evidence is emerging that inhibition of active 
ghrelin production by manipulating GOAT may provide a 
novel strategy for treatment of obesity. This chapter pro-
vides a review of GOAT, its tissue distribution and regula-
tion, enzyme characteristics, effects of the GOAT/ghrelin 
system on energy metabolism, and the effects of interfer-
ence of GOAT with physiological functions.  
DISCOVERY OF GHRELIN 
O-ACYLTRANSFERASE (GOAT)  
In 1984, Bowers et al. (Bowers et al., 1984) identified a 
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synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 
(GHRP-6), as a potent stimulator for growth hormone re-
lease in vitro and in vivo by an unknown mechanism distinct 
from growth hormone release hormone and somatostatin 
pathways. This observation indicated the presence of a 
unique receptor. As a peptide, GHRP-6 did not readily lend 
itself to optimization of pharmacokinetic properties by me-
dicinal chemistry. Subsequently, Bowers and other scien-
tists developed various synthetic peptidyl and nonpeptidyl 
molecules named growth hormone secretagogue (GHS) 
(Smith et al., 2004). In 1996, GHSs receptor was identified 
in porcine and rat anterior pituitary membranes as a 
G-protein-coupled receptor (Howard et al., 1996). Cell lines 
stably expressing the GHS-R were used for identification of 
endogenous GHS-R ligands. In 1999, Kojima et al. (Kojima 
et al., 1999) screened several tissue extracts and isolated the 
endogenous nature ligand for GHS-R from gastric extracts 
and named it ghrelin. The ghrelin amino acid sequence in 
rat was determined as GSSFLSPEHQKAQQRKESKKPPA 
KLQPR in which serine-3 (Ser3) is n-octanoylated. Oc-
tanoylation is necessary for binding and for activation of the 
GHS-R. The details of acylation and the enzyme that facili-
tates this modification remained elusive. 
In 2008, the enzyme responsible for ghrelin octano-  
ylation was identified independently by two research 
groups. Yang et al. (Yang et al., 2008a) provide the first 
evidence for ghrelin O-acyltransferase (GOAT). They de-
termined the portion of the mouse genome encoding 16 
membrane-bound O-acyl transferase (MBOAT) protein 
sequences. These investigators revealed that one of these 
MBOATs catalyzed the octanoylation of ghrelin by 
co-transfecting endocrine cells lines with ghrelin and 
MBOAT constructs. This MBOAT facilitating ghrelin acyl-
ation was then named ghrelin O-acyl transferase (GOAT) 
(Yang et al., 2008a). A series of transfection experiments on 
mouse pituitary AtT-20 cells, rat insulinoma INS-1 cells, 
and mouse insulinoma MIN-6 cells validated GOAT-   
dependent octanoylation of ghrelin in these rodent endo-
crine cell lines. Mutation of the serine at position 3 to ala-
nine prevented the acyl modification of ghrelin by GOAT, 
indicating that the presence of the third serine is essential 
for GOAT-dependent octanoylation of ghrelin (Yang et al., 
2008a). The studies demonstrated that proghrelin is oc-
tanoylated before reaching the Golgi where prohormone 
convertase 1/3 (PC 1/3) posttranslationally cleaves pro- 
ghrelin to form mature ghrelin (Zhu et al., 2006). These 
studies suggest that GOAT is present in the endoplasmic 
reticulum and catalyzes the acylation on proghrelin before 
being translocated to the Golgi. 
At the same time, Gutierrez et al. (Gutierrez et al., 2008) 
reported that a member of the MBOAT family is involved 
in ghrelin acylation in human medullary thyroid carcinoma 
(TT) cells. Silencing the GOAT gene by its specific siRNA, 
rather than siRNAs directed at other MBOAT members, 
inhibited ghrelin acylation in these cells. This study further 
supported the hypothesis that only GOAT contributes to the 
acylation of ghrelin (Gutierrez et al., 2008). To further ex-
clude effects of endogenous factors, these investigators used 
HEK-293 cells that neither express ghrelin nor GOAT. 
HEK-293 cells cotransfected with preproghrelin and GOAT 
started secreting octanoylated ghrelin. Further, octano-  
ylation of ghrelin was only achieved by GOAT, but not by 
other members of the MBOAT family, including MBOAT1, 
MBOAT2, MBOAT3, MBOAT5, human-BB1, porcupine, 
and FKSG89 (Gutierrez et al., 2008). Treatment of 
HEK-293 cell with a variety of substrate lipids including 
tetradecanoic acid caused acylation of ghrelin (Gutierrez et 
al., 2008). This result suggests that GOAT utilizes fatty acid 
substrates for acylation in addition to octanoic and decanoic 
acid. Considering the high degree of similarity in GOAT 
proteins across many vertebrates, HEK-293 cells were 
transfected with rat, mouse or zebrafish GOAT. All GOAT 
constructs resulted in successful octanoylation of human 
ghrelin, indicating that the function of GOAT is highly 
conserved across vertebrate species (Gutierrez et al., 2008).  
EXPRESSION AND DISTRIBUTION OF GOAT 
Tissue distribution of GOAT 
In mice, the highest levels of GOAT mRNA are expressed 
in the stomach and intestine followed by testis (Yang et al., 
2008a). In rats, GOAT mRNA is also expressed in hypo-
thalamus, stomach, intestine, ovary, serum, placenta, mus-
cle, heart, and adrenal glands (Gonzalez et al., 2008). 
Gutierrez et al. (Gutierrez et al., 2008) demonstrated that 
GOAT transcripts were most abundant in stomach and pan-
creas in humans. Studies indicate that stomach is the main 
source for production of acyl ghrelin. The number of 
GOAT-immunoreactive ghrelin cells in mouse stomach is 
much higher than rat stomach (Stengel et al., 2010). A study 
performed by An et al. (An et al., 2010) showed that GOAT 
mRNA and protein were present in the whole pancreas, iso-
lated islets and INS-1 cells. GOAT immunoreactive cells 
were mainly localized in the periphery of rat islets. GOAT 
is also expressed in the hypothalamus and pituitary and its 
levels increase in response to fasting in mice (Gahete et al., 
2010). Overall, GOAT appears to be predominantly ex-
pressed in stomach, brain and pancreas, all of which play 
important roles in the regulation of food intake and energy 
homeostasis.  
Regulation of GOAT expression 
A number of studies have reported that GOAT expression 
corresponds with organism energy levels (Gahete et al., 
2010). Levels of GOAT increase during fasting in mice, 
while decreasing in states of positive energy balance status 
such as diet-induced obese (DIO) and db/db mice (Xu et al., 
2009). Chronic malnutrition, achieved by 70% restriction in 
food intake for 21 d, was reported to increase in GOAT ex-
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pression in the gastric mucosa, while a 48 h fast demon-
strated no effect on GOAT mRNA transcription in rats 
(Gonzalez et al., 2008). In contrast, a 35% dietary food re-
striction for 5 mo has been reported to significantly reduce 
levels of GOAT in the stomach (Reimer et al., 2010). 
Kirchner et al. (Kirchner et al., 2009) reported that expres-
sion of GOAT was decreased after 12, 24, 36, and 48 h of 
fasting. Differences between studies may be attributed to 
species diversity and different energy restriction protocols.  
GOAT is regulated by insulin. Studies by An et al. (An  
et al., 2010) showed that insulin inhibited the expression of 
GOAT mRNA and its promoter activity via a mammalian 
target of rapamycin (mTOR)-dependent mechanism. mTOR 
was activated by insulin. Blocking mTOR signaling by ei-
ther rapamycin or overexpression of its negative regulators, 
tuberous sclerosis complex 1 (TSC1) or TSC2, increased 
the transcription and translation of GOAT. Pretreatment of 
INS-1 cells with rapamycin or overexpression of TSC1 or 
TSC2 attenuated the inhibitory effect of insulin on the tran-
scription and translation of GOAT (An et al., 2010). 
CHARACTERISTICS OF GOAT  
GOAT is a member of the MBOAT superfamily (Hofmann, 
2000), which is composed of many multi-spanning mem-
brane proteins conserved from prokaryotes to eukaryotes. 
MBOAT members have been shown to be critical for lipid 
biosynthesis, sterol acylation, and acyl modification of se-
creted proteins (Chen et al., 2004; Petrova et al., 2013; 
Takada et al., 2006). MBOAT family contains a highly 
conserved asparagine and an invariant histidine, which are 
proposed to be catalytic. Two additional regions of conser-
vation exist at the N- and C-terminal boundaries of loop 5 
on GOAT, where it adjoins surrounding hydrophobic re-
gions (Taylor et al., 2013). Knowledge of GOAT architec-
ture is important for a better understanding about how 
GOAT and other MBOATs function, and is a crucial pre-
condition for the discovery of selective inhibitors for these 
enzymes. 
Structure and architectural organization 
In 2013, Taylor et al. (Taylor et al., 2013) studied the archi-
tectural organization of GOAT by predicting topology 
through bioinformatics modeling, then using selective per-
meabilization to verify its predicted localization to the en-
doplasmic reticulum. Using the V5Glyc tag and gel shift 
blotting to probe the architecture around His-338, they iden-
tified two predominant bands suggesting generation of two 
separate GOAT species (Taylor et al., 2013). 
N and C termini were found to be on opposite sides of 
the membrane, requiring an odd number of transmembrane 
domains (TMs) (Taylor et al., 2013). Both positions 5 and 6 
were found to be cytosolic, suggesting that the strongly pre-
dicted, hydrophobic C6 does not cross the membrane. Myc 
tag labeling of the conserved domain of MBOAT localized 
residue Asn-307 to the cytosol. To determine the topology 
around position 9 and the location of the conserved His-338, 
a novel dual topology reporter, V5Glyc tag, was developed. 
This technique allowed sensitive readout of topology by 
both glycosylation gel shift Western blotting and selective 
permeabilization immunofluorescence microscopy. Because 
N-linked glycosylation only occurs in the endoplasmic re-
ticulum lumen, the luminal N-terminus of GOAT is glyco-
sylated completely, whereas the cytosolic C-terminus has no 
glycosylation. Position 9, immediately adjacent to the 
His-338 residue, was found to be luminal by both pep-
tide-N-glycosidase sensitivity analysis and selective per-
meabilization. Subsequent analysis with chromatography, 
sedimentation velocity and MALDI (matrix-assisted laser 
desorption-ionization)-TOF (time-of-flight) mass spectrom-
etry identified Met-56 as an alternate start codon. Because 
Met-56 is predicted to be the last (lumen) residue in TM-2, 
this finding suggests that GOAT lacking its first two TMs 
might be stable (Taylor et al., 2013). This may also be a 
physiologic product. Both M56A and M56I mutants elimi-
nated the production of the lower band detected by gel shift 
blotting.  
GOAT was verified to contain 11 transmembrane helices 
and one reentrant loop. Consistent with other member of the 
MBOAT family, the invariant residue His-338 and con-
served Asn-307 are located in the endoplasmic reticulum 
(ER) lumen and cytosol respectively, making it unlikely that 
both are involved in catalysis. Photo cross-linking of syn-
thetic ghrelin analogs and inhibitors demonstrates that the 
C-terminal region of GOAT is critical for binding reaction 
substrates, while lumenal His-338 mainly affects its activity 
(Taylor et al., 2013). 
Enzymatic characterization 
In 2012, Ohgusu et al. (Ohgusu et al., 2012) summarized a 
broad range of factors affecting the enzymatic activity of 
GOAT. Among these are detergents, acyl donors and sub-
strate of GOAT as well as temperature, pH and cations. 
Subcellular fractionation revealed that GOAT was a 
membrane-bound enzyme and its n-octanoyltransferase ac-
tivity partitions with the cell membrane fraction (Gutierrez 
et al., 2008; Yang et al., 2008a). Treatment of the mem-
brane fraction with CHAPS or Tween 80 retained GOAT 
activity. In contrast, treatment with six other detergents, 
including Triton X-100, Triton X-45, Lubrol, NP40, NP9, 
and Brij96v, attenuated or abolished GOAT activity. These 
findings indicate that CHAPS and Tween 80 stabilize the 
conformation of GOAT and are useful for solubilization of 
the enzyme (Ohgusu et al., 2012). 
To determine if GOAT utilizes only n-octanoyl-CoA as 
an acyl donor, Ohgusu et al. (Ohgusu et al., 2009) incubated 
various n-acyl-CoAs, including n-hexanoyl-, n-decanoyl-, 
n-palmitoyl-, and n-myristoyl-CoA with recombinant 
GOAT and desacyl-ghrelin. The reaction products were 
subjected to high-performance liquid chromatography 
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(HPLC) analysis to confirm the molecular structure by 
comparison with synthetic standard peptides. In addition to 
n-octanoyl CoA, GOAT modified the desacyl-ghrelin pep-
tide with other medium-chain acyl acids, such as 
n-hexanoyl-CoA and n-decanoyl-CoA. Long-chain fatty 
acids were not used as acyl donors. Further, kinetic studies 
using desacyl-ghrelin and three medium-chain acyl-CoAs as 
donor substrates revealed substrate preference as n-   
hexanoyl-CoA>n-octanoyl-CoA>n-decanoyl-CoA (Ohgusu 
et al., 2009). 
These investigators examined the peptide substrate spec-
ificity of GOAT using different length (four to eight amino 
acids) of synthetic peptide substrates derived from the 
N-terminal sequence of mammalian ghrelin (Ohgusu et al., 
2009). These substrates were shorter than desacyl-ghrelin 
with an-amide structure at the C-terminal. Short synthetic 
ghrelin peptides ranging from four to eight amino acids and 
n-octanoyl-CoA were used as peptide and acyl donor sub-
strates, respectively. HPLC analysis indicated that all five 
synthetic ghrelin-derived substrates delay the retention 
times for reaction products. The synthetic n-octanoyl-  
modified peptide GSS(C8:0)FLSPK-NH2 had the same re-
tention time as that of the GOAT-reacted GSSFLSPK-NH2 
product. These findings indicate that these five peptides 
serve as GOAT substrates that are modified by n-octanoic 
acid. Peptides as short as four amino acids are sufficient to 
serve as GOAT substrates (Ohgusu et al., 2009). 
The optimal temperature and pH for GOAT activity were 
also determined. The optimal reaction temperature was from 
37 to 50°C. GOAT activity was retained at 55°C but abol-
ished over 60°C (Ohgusu et al., 2012). Optimal pH for 
maximal specific activity was pH 7.0–7.5. The specific ac-
tivity reduced rapidly below pH 6.5 or over pH 8.5. Some 
cations have effects on GOAT activity as well. Recombi-
nant GOAT was activated by low concentrations but inhib-
ited by high concentrations of Mg2+ and Ca2+, while Fe3+ 
and Cu2+ potently inhibited GOAT activity. Ethylenedia-
minetetraacetic acid (EDTA) and ethylene glycol tetraacetic 
acid (EGTA) did not affect GOAT activity, indicating 
GOAT has no absolute requirement for cations (Ohgusu   
et al., 2012). 
GOAT/ACYL-GHRELIN SYSTEM AND 
ENERGY METABOLISM 
Ghrelin is the only known peripherally produced and cen-
trally acting peptide hormone stimulating food intake. 
Acyl-ghrelin promotes a positive energy balance by in-
creasing food intake and reducing energy expenditure, 
therefore leading to an increase in body weight and adipos-
ity (Tschop et al., 2000). As mentioned above, GOAT is 
responsible for ghrelin post-translational modification at its 
Ser3. The acylation is required for ghrelin to bind with and 
activate its receptor GHS-R1a. Thus, GOAT and acyl- 
ghrelin are critical for the biological functions of ghrelin- 
 
Figure 1  Roles of GOAT/acyl-ghrelin system in energy metabolism. 
Octanoylation of ghrelin (sequence as: GSSFLSPEHQKAQQRKES- 
KKPPAKLQPR) by ghrelin O-acyltransferase (GOAT) on its third amino 
acid (serine-3) is necessary for the hormone’s biological functions, Oc-
tanoylated ghrelin regulates food intake by inducing hyperphagia and in-
creasing gastrointestinal motility, modulates glucose metabolism by alter-
ing insulin secretion and sensitivity, as well as stimulates adiposity by 
increasing lipid storage and/or decreasing lipid expenditure. 
GHS-R1a signaling in hormonal secretions, memory and 
learning processes, food intake, body weight gain, insulin 
release, -cell survival, adiposity, energy homeostasis, in-
flammatory processes, as well as in the development and 
progression of several types of cancers. Here, we focus on 
their relevance to energy metabolism (Figure 1). 
GOAT/acyl-ghrelin system on ingestive behavior 
Acyl-ghrelin earns its name as the “hunger hormone” be-
cause circulating acyl-ghrelin levels rise during fasting and 
between meals, while decreasing in the post-prandial state 
(Cummings et al., 2001). The hormone exerts its orexigenic 
effects by acting on hypothalamic neurons crucial for the 
regulation of feeding behavior and energy metabolism. 
Acyl-ghrelin activates neuropeptide Y (NPY)- and agou-
ti-related peptide (AgRP)-producing neurons in the arcuate 
nucleus (Nakazato et al., 2001), probably through the 
mTORC1/S6K1 signaling dependent mechanism (Stevan- 
ovic et al., 2013) to increase the secretion of NPY, AgRP 
and gamma butyric acid (GABA). NPY subsequently mod-
ulates the activity of postsynaptic secondary order neurons 
in the paraventricular nucleus, dorsomedial nucleus and 
lateral hypothalamic area to stimulate food intake, while 
GABA inactivates proopiomelanocortin neurons and inhib-
its the anorectic melanocortin signaling pathway. Acyl- 
ghrelin reaches the hypothalamus through three different 
pathways: via the systemic circulation by crossing the 
blood-brain barrier, through vagal afferent nerves, and by 
local synthesis in the hypothalamus where it may exert 
paracrine effects (Lim et al., 2011). The regulation of food 
intake by acyl-ghrelin is tightly dependent on metabolic 
status. Administration of exogenous acyl-ghrelin induces 
hyperphagia only in free-feeding rats but not in animals 
under negative metabolic conditions such as fasting or in 
chronic food-restriction (Alen et al., 2013). Acyl-ghrelin has 
also been shown to increase energy intake in situations of 
impaired appetite or cachexia, a common problem in cancer 
patients (Molfino et al., 2013). 
Acyl-ghrelin is also a strong gastrokinetic agent, having 
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the motilin-like ability to stimulate motility in the gastroin-
testinal tract (Trudel et al., 2002). Acyl-ghrelin triggers  
the migrating motor complex in the fasted state (De Winter 
et al., 2004; Fujino et al., 2003; Tack et al., 2006) and ac-
celerates gastric emptying in the postprandial state in both 
rodents and humans (Asakawa et al., 2001; Levin et al., 
2006). Acyl-ghrelin accelerates the transit of the small in-
testine but not the colon (Trudel et al., 2002). The prokinet-
ic effect of acyl-ghrelin on gastrointestinal motility is medi-
ated through activation of vagal afferents because atropine 
or vagotomy blocks the contractions elicited by ghrelin in 
urethane-anesthetized rats (Fujino et al., 2003; Fukuda    
et al., 2004).  
GOAT/acyl-ghrelin system, insulin release and glucose 
metabolism 
Pharmacological treatment or genetic manipulation of ghr- 
elin in rodents indicates that GOAT/acyl-ghrelin system 
regulates glucose-stimulated secretion of insulin (GSIS). 
Despite the report by Lee et al. (Lee et al., 2002) showing 
that systemic administration of acyl-ghrelin enhances insu-
lin secretion in rats, most rodent data support the concept 
that acute systemic administration of acyl-ghrelin inhibits 
insulin secretion. Pharmacological inhibition of the 
GOAT/acyl-ghrelin system with a GOAT inhibitor (Barnett 
et al., 2010) or GHS-R1a antagonist (Esler et al., 2007) sig-
nificantly increases GSIS and improves glucose tolerance. 
These data indicate that antagonizing the GOAT/acyl- 
ghrelin system improves glucose tolerance by enhancing 
GSIS in rodents. Consistent with pharmacological studies, 
genetic ablation of either ghrelin or GOAT leads to im-
proved glucose tolerance and increased GSIS in mice fed a 
normal chow diet (Sun et al., 2006; Zhao et al., 2010). Fur-
ther, improvement in hepatic and peripheral insulin sensi-
tivities measured by hyperinsulinemic–euglycemic clamps 
has also been reported in ghrelin-deficient mice (Sun et al., 
2006). Although GOAT-deficient mice subjected to insulin 
tolerance testing demonstrate similar insulin sensitivity rel-
ative to wildtype littermates (Kirchner et al., 2013), a more 
rigorous measure, such as hyperinsulinemic–euglycemic 
clamp, is needed to determine whether GOAT-null mice 
have altered insulin sensitivity. 
Different from GOAT/acyl-ghrelin knockouts, mice 
lacking GHSR demonstrate similar glucose tolerance but 
decreased GSIS compared with wildtype littermates. This 
observation suggests that GHSR ablation improves insulin 
sensitivity (Lin et al., 2011; Longo et al., 2008). Data from 
hyperinsulinemic-euglycemic clamps showed a significant 
increase in glucose infusion rate, glucose disposal, and a 
decrease in endogenous glucose production in GHSR-null 
mice. These findings indicate that peripheral and hepatic 
insulin sensitivities are both enhanced in the absence of 
GHSR signaling (Lin et al., 2011; Qi et al., 2011).  
Chronic application of rapamycin has been associated 
with new onset diabetes in patients with organ transplanta-
tion. Studies by Xu et al. (Xu et al., 2012) have demon-
strated that systematic injection of rapamycin significantly 
increased gastric ghrelin/GOAT expression, as well as cir-
culating acyl-ghrelin. This effect is likely mediated by an 
increase in GOAT transcription induced by rapamycin. The 
derangement in glucose metabolism induced by systemic 
rapamycin was significantly attenuated by ghrelin receptor 
antagonism or genetic deletion (Xu et al., 2012). These 
findings suggest that GOAT/acyl-ghrelin contributes to ra-
pamycin induced glucose dysfunction.  
GOAT/acyl-ghrelin system and thermogenesis and en-
ergy expenditure  
Relative to the well-established role of ghrelin in the regula-
tion of feeding behavior, its actions in thermogenesis and 
energy expenditure remains to be fully elucidated. Studies 
have revealed a biphasic action of acyl-ghrelin on thermo-
genesis, reducing body temperature at low doses (Lawrence 
et al., 2002), while increasing it at high doses (Jaszberenyi 
et al., 2006). Consistent with this observation, ghrelin gene 
knockout mice showed an impairment in the control of body 
temperature under extreme thermic conditions (Szentirmai 
et al., 2009). Ghrelin may contribute to the regulation of 
thermogenesis via a central mechanism because areas of the 
hypothalamus located in the vicinity of cold-sensitive neu-
rons exhibit ghrelin-binding sites (Wiedmer et al., 2011). 
Contradicting this study, both GHSR-KO (Szentirmai et al., 
2009) and GOAT-KO mice (Heppner et al., 2013) main-
tained a similar body core temperature relative to wild type 
counterparts under thermic stress. Further, administration of 
acyl-ghrelin did not alter body temperature in mice, rats, 
and humans (Wiedmer et al., 2011). In this context, the ac-
tions of alternative ghrelin gene-derived peptides such as 
obestatin could be important. Obestatin has been shown to 
attenuate the hypothermic response of ghrelin gene KO 
mice (Szentirmai et al., 2009). These sometimes conflicting 
observations suggest a complex regulation of body temper-
ature by the GOAT/acyl-ghrelin system. 
GOAT/acyl-ghrelin system and lipid metabolism 
Chronic central administration of acyl-ghrelin increases 
adipose deposition independent of food intake in pair-fed 
animals. Although total energy expenditure and spontane-
ous physical activity remained unchanged, respiratory quo-
tient was significantly increased, indicating greater carbo-
hydrate metabolism instead of lipid substrate consumption. 
Further studies demonstrated that central ghrelin stimulated 
triglyceride (TG) uptake and lipogenesis, while inhibited 
lipid oxidation in white adipocytes. The mRNA expression 
of various fat storage–promoting enzymes such as lipopro-
tein lipase, acetyl-CoA carboxylase, fatty acid synthase, and 
stearoyl-CoA desaturase-1 were markedly increased 
(Theander-Carrillo et al., 2006), while levels of the rate- 
limiting enzymes in fat oxidation such as carnitinepalmito-
yltransferase-1 were significantly decreased. In brown 
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adipocytes, intracerebroventricular injection of ghrelin de-
creased the expression of uncoupling proteins (UCPs) in a 
dose-dependent manner. This effect was independent of 
acyl-ghrelin-induced hyperphagia, and was mediated by the 
sympathetic nervous system (Theander-Carrillo et al., 
2006). Intact -adrenergic signaling is required for acyl- 
ghrelin induced increases in adipose tissue deposits.  
Peripheral daily administration of acyl-ghrelin for two 
weeks caused a significant increase in fat mass as measured 
by dual energy X-ray absorptiometry (Tschop et al., 2000). 
As ghrelin receptor null mice were unresponsive to 
acyl-ghrelin, it is proposed that this effect is mediated by 
the ghrelin receptor GHS-R1a. This concept was further 
supported by the observation that blockade of the ghrelin 
receptor abolished the effect of acyl-ghrelin on adiposity 
(Davies et al., 2009). In vitro experiments demonstrated that 
ghrelin increases white adipose tissue volume by either 
stimulating adipogenesis or inhibiting lipolysis and lipid 
efflux from adipocytes. In cultured epididymal adipocytes, 
application of acyl-ghrelin decreased the expression of 
ABCG1, the primary mediator of cholesterol efflux 
(Vaughan and Oram, 2005), and inhibited glycerol release 
(Tsubone et al., 2005), leading to the increase lipid accu-
mulation in adipocytes.   
Acyl-ghrelin-induced lipid accumulation is not limited to 
white adipose tissues. In mouse liver, acyl-ghrelin signifi-
cantly elevated the number of lipid droplets, total lipid area 
and triacylglycerol content (Li et al., 2014) as well as lipo-
genesis related genes. In contrast, ghrelin demonstrated no 
effect on hepatic lipogenesis in GHSR1a null mice (Li et al., 
2014). The effects of acyl-ghrelin on lipogenesis were me-
diated by the mTOR/PPAR signaling pathway.  
RELATION BETWEEN GOAT/ACYL-GHRELIN 
SYSTEM AND OBESITY 
It has been well described that plasma acyl-ghrelin levels 
are negatively correlated to body mass index (BMI) (Shiiya 
et al., 2002), which means that lean phenotype is associated 
with high levels of acyl-ghrelin and obesity with low levels 
of ghrelin. The reasons for this negative relation are un-
known, but might be explained by the adaptive response of 
organism. Systemic or intracerebroventricular administra-
tion of ghrelin induces hyperphagia, weight gain, and in-
creased adiposity (Nakazato et al., 2001; Tschop et al., 
2000). Chronic central administration of ghrelin increases 
adipose deposition independent of food intake in pair-fed 
animals (Nakazato et al., 2001; Theander-Carrillo et al., 
2006). Consistent with these observations, ghrelin receptor 
null mice are protected against the full development of di-
et-induced obesity (Zigman et al., 2005). 
In addition to its expression in gastric mucosa, GOAT is 
present in the circulation with levels dependent on metabol-
ic status. In the clinical study performed by Goebel-Stengel 
et al. (Goebel-Stengel et al., 2013), subjects with normal 
weight, anorexic subjects, and obese subjects with BMI 
30–40, 40–50 and >50 were recruited. After overnight fast-
ing, anorexic patients showed reduced circulating GOAT 
protein levels whereas obese patients with BMI>50 had 
increased concentrations compared to normal weight con-
trols. In contrast to circulating GOAT, ghrelin levels were 
higher in anorexic patients. Plasma GOAT protein levels 
correlated positively with BMI, and negatively with ghrelin 
(Goebel-Stengel et al., 2013). These observations indicate 
that GOAT may counteract the adaptive changes of ghrelin 
observed under these conditions and potentially contribute 
to the development or maintenance of anorexia and obesity.  
PHYSIOLOGICAL ALTERATIONS OF GOAT 
KNOCKOUT MICE 
Generation of GOAT null mice has provided an indispensi-
ble tool to explore the physiological functions of acyl- 
ghrelin. Two GOAT knockout mouse lines have been re-
ported (Gutierrez et al., 2008; Zhao et al., 2010). Both 
demonstrated the absence of acyl-ghrelin in blood and sig-
nificantly higher levels of desacyl-ghrelin relative to 
wild-type littermates. With normal chow diet feeding, they 
had normal body weight and fat mass (Kirchner et al., 
2009). When fed a high fat diet (HFD), these GOAT 
knockout mice displayed significantly lower body weights 
compared to wild-type animals, without significant change 
in body composition. Challenging GOAT knockout mice 
with HFD rich in medium chain triglycerides significantly 
reduced body weight and fat mass compared to wild-type 
littermates (Kirchner et al., 2009). This effect is likely due 
to increased energy expenditure, since food intake was 
higher in the GOAT knockout mice (Kirchner et al., 2009). 
The other GOAT knockout mouse line generated by Zhao  
et al. (Zhao et al., 2010) showed identical body weight, 
body composition and food intake as wild-type littermates, 
whether fed normal chow diet or HFD. Further, weight loss 
curves remained the same when subjected to a severe (60%) 
caloric restriction protocol (Zhao et al., 2010). Although 
fasting blood glucose initially declined equally in wild-type 
and GOAT/ mice under 60% caloric restriction, glucose 
levels stabilized in wildtype mice while continuing to de-
cline in GOAT/ mice after day 4. On day 7, GOAT/ mice 
were moribund, while wildtype mice showed normal physi-
cal activity. Infusion of either ghrelin or growth hormone 
normalized blood glucose in GOAT/ mice and prevented 
death (Zhao et al., 2010), suggesting that acyl-ghrelin is 
required to maintain blood glucose levels through growth 
hormone secretion during periods of caloric restriction. 
GOAT-mediated acylation of ghrelin is a critical modu-
lator of food reward. Following 24-hour food deprivation, 
GOAT-deficient mice displayed an attenuated motivation 
for food in an operant responding model (Davis et al., 
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2012). Regarding hedonic feeding, ghrelin administration 
increased operant lever pressing for sucrose, peanut but-
ter-flavored sucrose or HFD pellets in rodents. On the other 
hand, GHSR antagonist reduced operant responding for 
sucrose solution (Finger et al., 2012; Landgren et al., 2012; 
Perello et al., 2010; Skibicka et al., 2012). GOAT knockout 
mice showed a decreased hedonic feeding response as ex-
amined in a “dessert effect” protocol, in which the intake of 
a palatable HFD “dessert” was evaluated in calorical-
ly-sated mice (Davis et al., 2012).  
Not only can ghrelin control food intake, it also affects 
macronutrient selection (Shimbara et al., 2004). Studies by 
Shin et al. (Shin et al., 2010) demonstrated that ghrelin, 
GOAT, GHS-R1a and prohormone convertase 1/3 (PC 1/3) 
were expressed in Type I, II, III and IV taste cells of mouse 
taste buds, indicating that they could play local modulatory 
roles in taste perception. In 2013, Cai et al. (Cai et al., 2013) 
revealed that both ghrelin/and GOAT/ mice exhibited 
reduced lipid taste sensitivity, while GOAT/ mice demon-
strated increased salty taste sensitivity compared to 
wildtype control littermates. Given the evidence of a posi-
tive correlation between overall fat preference and percent-
age of body fat in human studies (Mela and Sacchetti, 
1991), the ghrelin/GOAT system may play a local modula-
tory role in determining taste cell function and signaling. 
Taken together, these results suggest that the motivation to 
obtain food and macronutrient selection is regulated by en-
dogenous GOAT activity. 
In 2012, a metabolomics analysis of plasma samples and 
gene expression analysis of tissues taken from GOAT/ 
mice highlighted significant changes in bile acid metabo-
lites and relevant transporters (Kang et al., 2012). Serum 
metabolite profile analysis revealed secondary bile acids are 
increased by more than 2.5-fold in GOAT/ mice. This ef-
fect was attributed to increased expression of the ileal so-
dium-dependent bile acid transporter in the intestinal and 
biliary tract. Further, a number of up-regulated solute carrier 
family genes were identified by microarray analysis of the 
intestinal tract of GOAT/ mice (Kang et al., 2012). Among 
these was Slc5a12. Slc5a12 is highly expressed in the 
proximal regions of the small intestine and serves as a low 
affinity transporter for short-chain monocarboxylate, such 
as lactate, short-chain fatty acids, and -hydroxy-butyrate 
from dietary sources (Srinivas et al., 2005; Teramae et al., 
2010). These findings suggest an additional role of the 
ghrelin/GOAT system in the regulation of bile acid metabo-
lism.  
THERAPEUTIC STRATEGIES TARGETING 
GOAT/ACYL-GHRELIN SYSTEM 
Discovery of the importance of ghrelin acylation for its ac-
tivity has enriched the known repertoire of posttranslation-
al-modification processes and opened the possibility of as-
sessing the physiological role of ghrelin and desacyl ghrelin 
by targeting GOAT. Inhibition of GOAT is a novel strategy 
distinct from previous strategies such as inhibition of the 
synthesis and/or secretion of ghrelin. Inhibition of GOAT 
would impede the production of acyl-ghrelin and simulta-
neously increase the level of desacyl-ghrelin, which could 
also be beneficial for glucose homeostasis.  
GOAT inhibitor: GO-CoA-Tat 
Since GOAT is essential for the production of acyl-ghrelin, 
inhibition of the GOAT represents a novel approach to sup-
press the ghrelin system. A peptide based bisubstrate analog 
with potent inhibition of GOAT activity has been developed 
by Barnett and colleagues and named GO-CoA-Tat (Barnett 
et al., 2010). 
Discovery of GO-CoA-Tat 
Previous investigations on serotonin N-acetyltransferase, 
using bisubstrate analogs, showed that installing an acetyl 
bridge between the amine substrate and CoA potently inhib-
ited this enzyme (Khalil et al., 1999). This strategy has been 
also used for histone acetyltransferases (Lau et al., 2000). 
The bisubstrate analog GO-CoA-Tat has been designed 
based on the theory that if GOAT uses a ternary complex 
mechanism which templates octanoyl-CoA and ghrelin pep-
tide, then linking the two substrates with a non-cleavable 
bridge could combine the binding energies of the individual 
ligands without the entropic loss associated with forming 
the ternary complex (Barnett et al., 2010). To assure that the 
synthesis peptide would be recognized by GOAT, amino 
acids 1-10, which are highly conserved, were selected for 
coupling to octanoyl-CoA. An 11-mer HIV Tat-derived 
peptide sequence was attached to the C terminus via an 
amino-hexanoyl linker to enhance cell penetration (Barnett 
et al., 2010). In vitro studies on two cell lines stably ex-
pressing GOAT and preproghrelin showed that GO-CoA- 
Tat inhibited the production of acyl-ghrelin but not desacyl 
ghrelin. Administration of GO-CoA-Tat to wild type 
C57BL6 animals fed with a medium chain trigylceride 
(MCT) diet decreased serum levels of acyl-ghrelin with 
maximum inhibition 6 h after administration. Consistent 
with in vitro studies, there was no significant effect on se-
rum levels of desacyl ghrelin (Barnett et al., 2010). 
Effects of GO-CoA-Tat on energy metabolism 
Chronic GO-CoA-Tat treatment prevented the significant 
weight gain observed in vehicle-treated mice fed MCT-rich 
HFD (Barnett et al., 2010). Quantitative magnetic resonance 
measurements showed that mice treated with GO-CoA-Tat 
displayed significantly lower fat mass, but not lean mass 
(Barnett et al., 2010). Another study performed on Siberian 
hamsters also demonstrated significant effects of GO-CoA- 
Tat on food deprivation-induced increases in ingestive be-
havior (Teubner et al., 2013). After 48 h food deprivation, 
GO-CoA-Tat attenuated food foraging, food intake, and 
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food hoarding post-refeeding relative to animals treated 
with saline. In addition, GO-CoA-Tat treated mice showed 
lower blood glucose. 
Pre-treatment of human islet cells with GO-CoA-Tat sig-
nificantly increased insulin release in response to a glucose 
challenge, suggesting that acyl-ghrelin plays a direct role in 
blunting insulin response (Barnett et al., 2010). Similar re-
sults have been detected in mice treated with GO-CoA-Tat. 
These mice showed a significant increase in insulin release 
induced by glucose, which was accompanied by a reduction 
in blood glucose. The effects of GO-CoA-Tat on insulin 
release and glucose metabolism were significantly attenu-
ated in ghrelin knockout animals relative to wild-type mice 
(Barnett et al., 2010). These observations support the hy-
pothesis that GO-CoA-Tat effects on glucose homeostasis 
are mediated by inhibition of acyl-ghrelin.  
Peptide or nonpeptide small molecule inhibitors 
As a peptide-based inhibitor, GO-CoA-Tat has limitations. 
Synthetic derivatives are anticipated in order to further 
maximize pharmacodynamic and/or pharmacokinetic prop-
erties. This is crucial when used to treat obesity and type 2 
diabetes. Although early results are promising, the efficacy 
for obesity treatment by GO-CoA-Tat remains to be proven. 
It is important to note that although mice used in these 
studies were maintained on a high fat diet, they did not have 
pre-existing obesity at the beginning of the treatment. Obese 
humans or rodents may respond less well to GOAT inhibi-
tion as the ghrelin system is already suppressed (Patterson  
et al., 2011) 
In 2008, an acyl-ghrelin product analog Dap3-ghrelin was 
designed to block GOAT activity in an in vitro biochemical 
study (Yang et al., 2008b). GOAT recognizes several amino 
acids in proghrelin that surround the site of octanoylation at 
serine-3. A pentapeptide containing only the N-terminal five 
amino acids of proghrelin (GSSFL) inhibits the oc-
tanoylation of proghrelin only when its C terminus is ami-
dated. The mutant GSAFL-NH2 pentapeptide also inhibits 
GOAT. Thus, the unacylated pentapeptide appears to inhibit 
GOAT by competing for the peptide binding site and not 
necessarily by serving as substrate for octanoylation. Oc-
tanoylation of proghrelin is inhibited more efficiently when 
the amidated pentapeptide contains an octanoyl in ester 
linkage to serine-3, thereby mimicking the product of the 
reaction. Inhibitory activity is significantly increased when 
full-length ghrelin (1–28) or the amidated ghrelin pentapep-
tide contains an octanoylated diaminopropionic acid (Dap) 
in place of the octanoylated serine at residue 3 (Yang et al., 
2008b). The increased inhibitory potency of the octanoylat-
ed ghrelin peptides with an amide linkage at residue 3, in-
stead of an ester linkage, may help guide the design of po-
tent small molecule inhibitors of GOAT. 
In 2011, Garner’s group (Garner and Janda, 2011) identi-
fied two potential non-peptide small molecule antagonists 
of GOAT by using an enzyme assay based on cat-ELCCA. 
Two compounds were discovered and named as compounds 
3a and 3b; both were found to exhibit dose-dependent an-
tagonism of GOAT. Based on the structures of compounds 
3a and 3b, these compounds may block octanoyl-CoA from 
binding to GOAT since each contains a long alkyl chain 
similar to that found in octanoyl-CoA. It remains to be de-
termined whether these non-peptide antagonists of GOAT 
are more potent than their peptide counterparts. 
Targeting GOAT versus GHS-R1a 
Two different strategies have been developed to block 
ghrelin receptor (GHS-R1a) signaling: antagonizing ghrelin- 
induced signaling or blocking the high constitutive activity 
by an inverse agonist. These strategies have led to the eval-
uation of a group of GHS-R1a neutral competitive antago-
nists and inverse agonists. Unfortunately, no ghrelin recep-
tor antagonist is currently available in the market, mainly 
due to deficient efficacy, selectivity, low potency, poor bi-
oavailability or side effects. 
Directly targeting the biosynthesis of the active acyl- 
ghrelin by inhibiting GOAT, offers several potential ad-
vantages over receptor antagonism. First, enzyme inhibitors 
are not required to cross the blood-brain barrier, because the 
main source of ghrelin/GOAT is from stomach, while many 
of the key action sites for ghrelin receptor antagonist are 
located in the brain. Second, receptor antagonists may drive 
higher acyl-ghrelin production and increase acyl/desacyl 
ghrelin ratios, which will blunt their long-term efficacy. A 
similar strategy has been demonstrated to be efficient for 
treatment of lipid dysfunction and some types of cancer by 
targeting other GOAT-related MBOAT family members. 
Finally, it is easier to develop small-molecule inhibitors of 
GOAT than receptor antagonists or inverse agonists. 
Tissue specific interference of GOAT  
At present, data assessing tissue specific regulation of 
GOAT expression are lacking. Tissue-specific genetic abla-
tion of GOAT will enable clarification of the paracrine role 
of ghrelin in different tissues. Considering levels of expres-
sion and functional relevance, particular emphasis should be 
given to the stomach, pancreas and hypothalamus. Another 
question is whether GOAT is regulated in response to the 
physiological environment. This seems likely to be the case 
because acyl-ghrelin levels fall significantly as the result of 
long-term fasting despite an increase in total ghrelin con-
centration.  
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